Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
PY

NASDAQ · PYPD

PolyPid Ltd.

Healthcare · Biotechnology

$5.39

Down-$0.20 (-3.58%)

Updated Nov 2, 2026, 7:12 AM

SID Score

5.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
40.46M
P/E ratio
-1.48
Dividend yield
0.00%
52-week range
$3.50 – $5.84
Volume
101.56K
Avg. volume
80.67K

Price performance · PYPD

PYPD price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

PYPD closed at $5.39 after 20 trading sessions, up 3.65% for the selected period.

Last close
$5.39
Period change
+3.65%
Period low
$4.72
Period high
$5.78
Daily close
View OHLC price history
PYPD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$5.54$5.59$5.38$5.39101.56K
Oct 29, 2026$5.84$5.84$5.55$5.5993.87K
Oct 28, 2026$5.77$5.80$5.54$5.78135.02K
Oct 27, 2026$5.34$5.79$5.34$5.77229.1K
Oct 26, 2026$5.25$5.365$5.17$5.2996.69K
Oct 23, 2026$5.14$5.25$5.11$5.25104.23K
Oct 22, 2026$5.02$5.19$4.92$5.13155.52K
Oct 21, 2026$5.19$5.21$5.00$5.07137.08K
Oct 20, 2026$4.88$5.17$4.7702$5.15109.51K
Oct 19, 2026$5.00$5.0911$4.77$4.88110.95K
Oct 16, 2026$4.82$4.90$4.72$4.72150.74K
Oct 15, 2026$4.70$4.97$4.61$4.90120.6K
Oct 14, 2026$4.89$4.95$4.75$4.83133.08K
Oct 13, 2026$5.04$5.08$4.80$4.8893.37K
Oct 12, 2026$5.07$5.1001$5.00$5.0277.64K
Oct 9, 2026$4.91$5.16$4.90$5.0760.18K
Oct 8, 2026$4.92$4.99$4.75$4.9088.87K
Oct 7, 2026$5.11$5.19$4.90$4.95115.1K
Oct 6, 2026$5.22$5.24$5.05$5.1386.56K
Oct 5, 2026$5.28$5.33$5.03$5.20102.02K

Latest PYPD news

The latest Smart Investors Daily articles mentioning PYPD.

Stock researchCompany · Overview

PYPD research

Overview

Company profile and research snapshot.

Company profile

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$9.00
Implied upside
—
Analysts
10
PYPD recent ratings
DateFirmRatingTarget
Oct 27, 2026OppenheimerOutperform—
Jul 21, 2026HC Wainwright & Co.Buy—
Feb 11, 2026HC Wainwright & Co.Buy—
Nov 13, 2025Roth CapitalBuy—
Aug 14, 2025Craig-HallumBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026

PETACH TIKVA, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its third quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 11, 2026. The Company will host a conference call and webcast at 8:30

Yahoo · Oct 29, 2026

PolyPid Targets 2027 D-PLEX100 Launch, Unveils Diabetic Foot Infection Program

PolyPid (NASDAQ:PYPD) outlined plans to expand its commercial and development strategy through 2030 at an investor day, as the company approaches a November 28, 2026, FDA action date for its D-PLEX100 surgical-site infection prevention product candidate. Chief Executive Officer Dikla Czaczkes Aksel

Yahoo · Oct 28, 2026

PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections

Company to host virtual Investor Day today at 11:30 AM ET, featuring key opinion leader Warren S. Joseph, DPM, FIDSA All scheduled FDA interactions on track and aligned with D-PLEX₁₀₀ November 28, 2026 PDUFA goal date PolyPid introduces PD01B, a new product candidate targeting hyper-localized, controlled-release antibiotic treatment of diabetic foot infections, based on the Company’s proprietary Kynatrix technology PD01B planned to be developed as a new NDA; pre-IND meeting and first-in-human st

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By